SILVER SPRING, MD. – A Food and Drug Administration advisory panel recommended that a contraindication or warning be added to the labels of injectable corticosteroids, specifically pertaining to transforaminal administration of particulate steroid formulations administered into the cervical spine, at a meeting held to address serious neurologic events associated with epidural steroid injections.
The FDA convened the Nov. 24-25 meeting of its Anesthetic and Analgesic Drug Products Advisory Committee to discuss the available evidence of the benefits of epidural steroid injections (ESIs), widely used off label to treat back pain, and the serious neurologic adverse events associated with ESIs. These events include strokes, paraplegia, quadriplegia, spinal cord infarction, and deaths, and they are the basis of the class warning added to the labels of these products this year.
In April 2014, the FDA issued a safety communication about these reports, warning that “injection of corticosteroids into the epidural space of the spine may result in rare but serious adverse events, including loss of vision, stroke, paralysis, and death.” An estimated 9 million ESIs are administered each year in the United States.
The panel voted 15-7, with one abstention, in favor of a contraindication, while those voting no supported a warning as more appropriate. The original voting question on the agenda was whether all epidural steroid injections should be contraindicated, but the FDA reworded the question because the panelists felt it was too broad.
Dr. Michael Weisman, director of the division of rheumatology at Cedars-Sinai Medical Center and professor of medicine at the University of California, Los Angeles, said that, considering the wide variety of conditions treated with ESIs and the complicated anatomy of the spine, the benefits of depot formulations, particularly in the cervical spine, do not outweigh the significant risks. The risk is small, “but when it happens, it is very significant,” he said.
Dr. Jeffrey Kirsch, professor and chair of the department of anesthesiology and perioperative medicine at Oregon Health and Science University, Portland, supported the contraindication because “it’s too risky to administer the particulate medication in the cervical region, because of the risk of intravascular and intraarterial injection.”
In the medical literature, corticosteroids are classified as particulate or nonparticulate formulations, but the FDA uses the terms suspension or solution to classify steroids. Some studies have suggested that the risks and benefits of the two formulations may be different, and the agency has been criticized for not distinguishing between particulate and nonparticulate products in the warning statement.
Based on the available data, which had substantial limitations, the panelists were most concerned with the risks of epidural injections of particulate steroid products administered into the cervical spine with a transforaminal (TFA) approach because of a greater risk of accidental injection into the vasculature. They also noted that the risks were not limited to TFA cervical administration or to particulate products. As one panelist put it, “Why would anybody want sludge injected into their artery that goes to the brain?”
Based on the available evidence, the panel generally agreed that ESIs can have moderate beneficial effects in treating back pain, with substantial variations between patients, and that these benefits should be considered in the context of the risks and benefits of alternative therapies. They also said that there was not enough evidence to support a particular injection method or location or steroid formulation as superior. As one panelist pointed out, depot formulations may be more effective than nondepot formulations, but the differences are marginal and the risks are greater. One panelist supported a contraindication for all particulate injections for epidural use.
The FDA has been evaluating serious neurologic events associated with ESIs since 2009, after being contacted by an anesthesiologist about the risk of catastrophic neurologic injuries associated with TFA epidural injections of depot steroid formulations.
Continued on next page >>